Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2014, specifically dated December 4, 2014. The report details a registered direct offering of American Depositary Shares (ADSs) and warrants entered into on December 2, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, or existing debt figures. The primary financial data relates to the capital raise transaction:
- Gross Proceeds: Expected aggregate gross proceeds of $8,000,000.
- Offering Price: $4.45 per ADS.
- Shares Issued: 1,797,753 ADSs.
- Warrants Issued: 898,877 warrants to purchase ADSs at an exercise price of $4.45.
- Transaction Costs: A 6% cash placement fee plus a 1% expense allowance (capped at $37,500) payable to the placement agent.
Material Changes
The material change reported is the execution of Securities Purchase Agreements for a registered direct offering. This transaction represents a significant increase in the company's share count and potential dilution through the issuance of new ADSs and warrants. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Outlook and Closing: The closing of the offering is expected on or about December 8, 2014, subject to customary closing conditions.
Risks and Contingencies: The filing includes a warning concerning forward-looking statements. The closing is not guaranteed and is subject to various conditions and contingencies. If these conditions are not satisfied, the offering may not close. Additionally, the warrants and underlying ADSs are unregistered and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption.
Management Commentary: The company engaged H.C. Wainwright & Co., LLC as the placement agent and Roth Capital Partners LLC as a financial advisor. The placement agent agreed to relinquish half of its cash fee and compensation warrants to Roth Capital Partners.
Investor Verification Checklist
- Verify the actual closing date of the offering, as the December 8, 2014 date is subject to conditions.
- Confirm the final number of ADSs and warrants issued upon closing.
- Review the full text of the Securities Purchase Agreements (Exhibit 10.2) and Warrant terms (Exhibit 10.3) for specific adjustment provisions and exercise restrictions.
- Assess the impact of the 6% placement fee and expense allowance on the net proceeds received by the company.
- Monitor future filings for the registration status of the ADSs underlying the warrants, which affects their exercisability on a cashless basis after six months.